Dennis Slamon
University of California, Los Angeles
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dennis Slamon as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:47 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT02708680 · Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead InSyndax Pharmaceuticals · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Protocol and Data Management (CPDM)P30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2009 to 2026 · $622,557 awarded in 2026Same name and institution; not confirmed by an ID
- The Transcription Factor SLUG may Drive the Progression of Akt and HER2/neuU54CA143930 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 2009 to 2011 · $37,703 awarded in 2011Same name and institution; not confirmed by an ID
- Signal Transduction in OncogenesisP01CA032737 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 1992 to 2006 · $1,555,483 awarded in 2006Same name and institution; not confirmed by an ID
- Academic Training in Medical OncologyT32CA009297 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 1991 to 2005 · $286,323 awarded in 2005Same name and institution; not confirmed by an ID
- PHASE I STUDY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS USING SCH58500M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 1998 to 2001 · $207,266 awarded in 2001Same name and institution; not confirmed by an ID
- CLINICAL CANCER RESEARCH DEVELOPMENTK12CA001714 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 1992 to 1996 · $171,847 awarded in 1996Same name and institution; not confirmed by an ID
- ONCOGENES IN PHYSIOLOGIC AND PATHOLOGIC STATESR01CA036827 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 1985 to 1996 · $263,340 awarded in 1996Same name and institution; not confirmed by an ID
- SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE/BREAST CANCERP20CA058197 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 1992 to 1994 · $216,169 awarded in 1994Same name and institution; not confirmed by an ID
- ACADEMIC TRAINING IN HEMATOLOGYT32DK007285 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 1992 to 1993 · $177,738 awarded in 1993Same name and institution; not confirmed by an ID
- CLINICAL STUDIES OF BIOLOGICAL RESPONSE MODIFIERSN01CM087289 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · fiscal years 1991 to 1993 · $656,378 awarded in 1993Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:47 UTC. The ranking covers the 200 most relevant of 83 PubMed records, and a shared surname and initials can bring in a namesake. All 83 on PubMed
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med · 20018,942 citationsRCR 183.5
- Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.J Clin Oncol · 20022,489 citationsRCR 48.7
- Palbociclib and Letrozole in Advanced Breast Cancer.N Engl J Med · 20162,383 citationsRCR 75.8
- 2,256 citationsRCR 48.3
- Adjuvant trastuzumab in HER2-positive breast cancer.N Engl J Med · 20112,138 citationsRCR 54.1
- 1,560 citationsRCR 45.3
- 1,471 citationsRCR 45.8
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.N Engl J Med · 20201,043 citationsRCR 46.1
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.N Engl J Med · 20181,016 citationsRCR 33.5
- 909 citationsRCR 29.7